Navigation Links
IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant Enterococci

CAMBRIDGE, Mass., Sept. 21, 2011 /PRNewswire/ -- IntelligentMDx (IMDx) announced today that it has received CE-Mark for its second automated molecular test for the Abbott FDA cleared m2000 instrument. The IMDx™ VanR for Abbott m2000™ test accurately detects and distinguishes the vanA and vanB genes most commonly found in vancomycin-resistant enterococci (VRE) in specimens from patients at risk for colonization or infection. Detection of both the vanA and vanB genes allows for identification of a higher number of at-risk patients than existing tests that only target the vanA gene. Like the recently introduced CE-marked IMDx C. difficile for Abbott m2000 test, the IMDx VanR for Abbott m2000 test offers a high-throughput solution for early detection of pathogens associated with common healthcare-associated infections.

VRE are bacteria which have become resistant to the antibiotic vancomycin, and are responsible for a variety of healthcare-associated infections, including those of surgical wounds, urinary tract, and bloodstream. VRE are transmitted through contact and are most often seen in hospitals due to the high prevalence of contaminated surfaces and hand to hand contact.

The automated nature of the IMDx VanR for Abbott m2000 test allows laboratories to obtain results for up to 48 patient samples in less than 3 hours, and up to 94 patient samples in less than 4 hours. The IMDx VanR for Abbott m2000 test exhibits high sensitivity and specificity when compared to traditional chromogenic agar methods, with values of 96.4% and 98.0%, respectively.

"At IMDx, we have developed unique proprietary software analytic tools, enabling us to produce tests that are sensitive, cost-effective, and rapid alternatives to existing culture-based screening methods for vancomycin-resistant infections. We are proud to offer physicians the ability to make timely, informed decisions about patient care in order to aid in preventing the spread of healthcare-associated infections," says Alice Jacobs, MD, Chairman & CEO of IMDx.

About IMDx

Based in Cambridge, MA, IMDx ( is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.

Contact:  Renda Hawwa, 617-871-6417,

SOURCE IntelligentMDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verification Studies of IntelligentMDxs Proprietary Molecular Diagnostic Assay Process Have Been Completed
2. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
3. Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests
4. Intelligent Medical Devices, Inc. (IMDx) Introduces a CE-Marked Automated Assay for the Detection of C. difficile Including Hypervirulent Strains
5. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
6. Dr. Dello Russo Introduces the New EYE-Q Lasik
7. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
8. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
9. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
10. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):